Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer
Open Access
- 1 November 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (11) , 2061-2063
- https://doi.org/10.1093/clinchem/47.11.2061
Abstract
Prostate cancer (PCa) is the most frequent carcinoma in men and is often complicated by skeletal metastasis (1). Because bone scintigraphy, the standard method of monitoring metastatic bone involvement, is expensive, lacks specificity, and is not particularly suitable for the follow-up of patients, various metabolic bone markers have been studied as indicators for bone metastasis in PCa patients (2)(3). Markers that reflect osteoblast proliferation, e.g., skeletal alkaline phosphatase (sALP), are reportedly useful, which is consistent with the osteoblastic reactions seen in the skeletal metastases (4).Keywords
This publication has 13 references indexed in Scilit:
- Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the boneJournal of Clinical Investigation, 2001
- ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical StudiesClinical Chemistry, 2001
- Osteoprotegerin and rank ligand expression in prostate cancerUrology, 2001
- The serum level of the amino‐terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to boneBJU International, 2001
- Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligandsCytokine & Growth Factor Reviews, 2001
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Markers of bone turnover for the management of patients with bone metastases from prostate cancerBritish Journal of Cancer, 2000
- Immunological Characterization of Circulating Osteoprotegerin/Osteoclastogenesis Inhibitory Factor: Increased Serum Concentrations in Postmenopausal Women with OsteoporosisJournal of Bone and Mineral Research, 1999
- Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphataseClinical Chemistry, 1998
- Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for WindowsScandinavian Journal of Clinical and Laboratory Investigation, 1995